TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) is now available.
Shandong Boan Biotechnology Co., Ltd. reported a substantial increase in revenue for the year ended 31 December 2024, reaching approximately RMB726.3 million, a 17.5% rise from the previous year. This growth was driven by the successful commercialization of three products and increased licensing revenue. The company’s cost of sales decreased, leading to a higher gross profit of RMB542.6 million, up by 32.7%. Despite an increase in selling and distribution expenses, the company managed to reduce its research and development expenses due to capitalizing R&D investments into deferred development costs as key projects advanced to phase 3 clinical trials. This financial performance underscores the company’s strengthened market position and effective strategy in the biopharmaceutical industry.
More about Shandong Boan Biotechnology Company., Limited. Class H
Shandong Boan Biotechnology Co., Ltd. is a biotechnology company based in China. The company focuses on the development and commercialization of biopharmaceutical products, with a strong emphasis on the domestic market. Its primary products include Boyounuo® (BA1101) and Boyoubei® (BA6101), which have contributed significantly to its revenue growth.
YTD Price Performance: -7.07%
Average Trading Volume: 223,492
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.65B
See more data about 6955 stock on TipRanks’ Stock Analysis page.